|
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States.
PRD-101 is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT® (DNA Optimizing Technology). The drug leverages the company's nucleotide-based Advanced DOT™ drug delivery platform, designed to enable efficient loading of therapeutics and improve pharmacokinetics.
The Phase 1 clinical trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of PRD-101.
"The FDA clearance of our IND application marks an important milestone for PRD-101. Through this Phase 1 trial, we aim to further characterize PRD-101 and continue advancing our oncology pipeline," PharmaResearch stated.
About PharmaResearch's PRD-101
PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimizing technology (DOT®) in nanoparticle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive licenses associated with PRD-101, marking a milestone in the company's innovative endeavors.
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy.
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life through regenerative medicine. With a diverse portfolio that includes medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients—DOT® PDRN and DOT ® PN—which are protected by a suite of patents. Headquartered in Gangneung-si, Gangwon-do, South Korea, PharmaResearch also has a subsidiary in Costa Mesa, California.
For more information about PharmaResearch, visit https://pharmaresearch.com/en
SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO: Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial in the United States.
PRD-101 is a next-generation nano anticancer drug candidate formulated using nucleotide fragments produced through PharmaResearch's proprietary DOT® (DNA Optimizing Technology). The drug leverages the company's nucleotide-based Advanced DOT™ drug delivery platform, designed to enable efficient loading of therapeutics and improve pharmacokinetics.
The Phase 1 clinical trial will be conducted across up to seven clinical sites in the United States and is expected to enroll approximately 90 patients with locally advanced or metastatic solid tumors. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of PRD-101.
"The FDA clearance of our IND application marks an important milestone for PRD-101. Through this Phase 1 trial, we aim to further characterize PRD-101 and continue advancing our oncology pipeline," PharmaResearch stated.
About PharmaResearch's PRD-101
PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimizing technology (DOT®) in nanoparticle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive licenses associated with PRD-101, marking a milestone in the company's innovative endeavors.
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy.
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life through regenerative medicine. With a diverse portfolio that includes medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients—DOT® PDRN and DOT ® PN—which are protected by a suite of patents. Headquartered in Gangneung-si, Gangwon-do, South Korea, PharmaResearch also has a subsidiary in Costa Mesa, California.
For more information about PharmaResearch, visit https://pharmaresearch.com/en
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101
POMONA, Calif., April 4, 2026 /PRNewswire/ -- As families prepare for Easter, a season defined by family reunions, outdoor festivities, and shared traditions, Nework, an audiovisual and collaborative solutions provider for education, business, and home, is redefining seasonal entertainment with its MoveMate Series Portable TVs. Designed for ultimate mobility and premium performance, the MoveMate lineup offers a sophisticated way to bring digital entertainment into every corner of the holiday celebration. To celebrate the season, Nework has launched its Spring Sale, featuring an instant $60 discount across the series. The MoveMate AI is now available for $599.99, while the MoveMate Hi-Fi flagship is priced at $689.99.
Redefining Holiday Entertainment
The Nework MoveMate Hi‑Fi exemplifies how technology can enrich Easter gatherings with minimal effort. During backyard brunches or patio parties, the device functions as a mobile backdrop, effortlessly rolling from the kitchen to the lawn on its silent casters. Its professionally tuned 44W audio system, complete with quad speakers and a dedicated subwoofer, fills open spaces with warm, room‑enveloping sound, making it ideal for holiday playlists, family movies, or ambient visuals that add charm to spring celebrations. The 27‑inch FHD display provides crisp imagery at any angle, while the rotatable and height‑adjustable design ensures clear views whether placed beside a picnic table or within a cozy indoor corner.
As spring evenings warm up, outdoor movie nights have become a beloved seasonal ritual. After an afternoon of egg hunts, the MoveMate Hi‑Fi can be wheeled onto the grass to create an instant open‑air cinema. Its powerful audio performance strengthens the sense of immersion, while Bluetooth, Wi‑Fi 6, and streaming app compatibility ensure quick and smooth setup. For families who enjoy capturing shared memories on camera, the device's HD camera adds a layer of convenience and security with a physical privacy cover.
A Modern Gift for the Modern Home
For families seeking a standout Easter surprise, the MoveMate Hi‑Fi also lends itself to creative gifting. Instead of filling oversized baskets with candy or toys, households are presenting the portable TV as the "grand prize" of Easter morning. As a premium yet practical gift, it brings long‑term entertainment value through its smart system, which offers access to streaming platforms, cooking apps, video‑call tools, and more. The built‑in battery delivers up to eight hours of wireless use, supporting the spontaneity of holiday activities.
The Nework MoveMate AI presents another compelling option for family use and Easter gifting. With a 27‑inch multi‑touch display, up to 16 hours of battery life, and EDLA‑certified Android 14 smart features, the MoveMate AI offers versatility for both entertainment and productivity. It functions as a cooking companion during Easter meal preparations, streaming step‑by‑step recipes or hosting video chats with distant relatives. Its adjustable stand and five‑wheel mobility make repositioning effortless in busy kitchens or living rooms, while the Qualcomm octa‑core processor ensures smooth performance across apps, from YouTube tutorials to streaming platforms.
This renewed focus on adaptive home technology aligns with Nework's vision. "At Nework, technology should adapt to people's lives, not the other way around. The MoveMate series is designed to bring flexibility, connection, and joy to everyday moments, especially during meaningful occasions like Easter," said the CEO of Nework.
As families across the United States embrace more flexible, mobile, and immersive entertainment experiences, the MoveMate Series continues to stand out as a forward‑thinking lifestyle upgrade. Whether used indoors for cooking, outdoors for movie nights, or as a creative Easter morning reveal, it offers a premium blend of functionality and festive delight.
For more information, please visit https://nework.us/, or connect with Nework:
Facebook: https://www.facebook.com/neworkus
LinkedIn: https://www.linkedin.com/company/nework-us/
X: https://x.com/Nework_us
Instagram: https://www.instagram.com/nework.us
YouTube: https://www.youtube.com/@Nework-us
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Elevate Easter Celebrations: Nework Introduces MoveMate Series Portable TVs for Effortless Family Moments
